It is well known that excess iron storage in liver tissue associates with liver injury, we evaluated the efficacy of dietary iron reduction on patients with chronic hepatitis C. In sixteen patients with chronic active hepatitis (CAH) and twelve patients with chronic persistent hepatitis (CPH), we measured serum transaminase, serum iron, ferritin, P-III-P, hyaluronic acid and mean daily intake of iron. At both three and six months after the guidance of iron reduction, daily iron intake reduced significantly. Serum transaminase levels were also decreased signifi cantly in CAH and CPH groups at six months after the guidance. In CAH group, P-III-P levels were also improved in 9 of 16 (56%) patients during the follow-up period. These results suggest that dietary iron reduction is effective for the patients with chronic hepatitis C.